Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
248.91
+2.54 (1.03%)
Jan 8, 2026, 4:00 PM EST - Market closed
Krystal Biotech Employees
Krystal Biotech had 275 employees as of December 31, 2024. The number of employees increased by 46 or 20.09% compared to the previous year.
Employees
275
Change (1Y)
46
Growth (1Y)
20.09%
Revenue / Employee
$1,356,960
Profits / Employee
$723,309
Market Cap
7.22B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 275 | 46 | 20.09% |
| Dec 31, 2023 | 229 | 19 | 9.05% |
| Dec 31, 2022 | 210 | 91 | 76.47% |
| Dec 31, 2021 | 119 | 44 | 58.67% |
| Dec 31, 2020 | 75 | 22 | 41.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KRYS News
- 2 hours ago - Krystal Biotech, Inc. (KRYS) Discusses Positive Interim Results and Next Steps for Cystic Fibrosis Program KB407 Transcript - Seeking Alpha
- 6 weeks ago - Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Krystal Biotech: Vyjuvek Gene Therapy Well Positioned For Growth - Seeking Alpha
- 2 months ago - Krystal's Q3: Platform Designation Adds Pipeline Leverage As Vyjuvek Scales (Rating Upgrade) - Seeking Alpha
- 2 months ago - Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin - Benzinga
- 4 months ago - Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label - GlobeNewsWire
- 4 months ago - Krystal Biotech: A "Strong Buy" Despite KB707 Melanoma Tumor Targeting Update - Seeking Alpha